Tarsus Pharmaceuticals, Inc.
TARS
$79.44
-$0.53-0.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.62% | 31.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.62% | 31.05% | |||
| Cost of Revenue | 12.65% | 11.27% | |||
| Gross Profit | 16.42% | 37.66% | |||
| SG&A Expenses | 5.46% | 21.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.71% | 19.34% | |||
| Operating Income | 34.51% | 15.59% | |||
| Income Before Tax | 38.13% | 19.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 38.13% | 19.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 38.13% | 19.03% | |||
| EBIT | 34.51% | 15.59% | |||
| EBITDA | 35.26% | 15.84% | |||
| EPS Basic | 38.48% | 24.78% | |||
| Normalized Basic EPS | 38.49% | 28.53% | |||
| EPS Diluted | 38.48% | 24.78% | |||
| Normalized Diluted EPS | 38.49% | 28.53% | |||
| Average Basic Shares Outstanding | 0.58% | 7.66% | |||
| Average Diluted Shares Outstanding | 0.58% | 7.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||